News Releases

News & Resources

News Releases

Synteract Increases Presence in East Coast Biotech Markets Through Presentations at OCT Southeast and Clinical Trial Collaborations Conferences

SAN DIEGO – March 14, 2016 – Senior leaders from West Coast-based, full-service contract research organization Synteract will offer presentations during the OCT Southeast conference, March 15-16, in Cary, North Carolina, and during the Clinical Trial Collaborations event, March 21-22, in Boston. The company’s international thought leadership continues to grow through its presence at global industry events in 2016. Synteract’s team of experts also will be in attendance to discuss the company’s experience in collaborating with emerging to mid-sized pharma, biotech and device companies to efficiently bring tomorrow’s treatments to the patients who need them.

At OCT Southeast, Synteract will exhibit in booth #40 and Senior Project Manager Thomas Barfield will offer insights on “The patient-centric approach to successfully planning and managing your clinical program,” from 2:00-2:30 p.m. on Wed., March 16th. Thomas shares a patient-centric focus from two perspectives: his personal experience as a clinical research professional and as a surviving family member. His insights include:

  • Shifting the perspective from “subject” to “patient”
  • Improving the drug development process by using evolving approaches to include the voice of the patient and an assessment of patient preference
  • Developing clinical protocols to minimize the impact on patients’ lives and maximize enrollment and retention

Chief Administrative Officer Stewart Bieler will participate on a panel discussing “Where is There Potential for CROs to Collaborate?” at 4:35 pm on Monday, March 21, during the Clinical Trial Collaborations conference. The panel will address questions such as:

  • Is there a market for collaboration to promote patient centricity?
  • Is there enough differentiation or unique tools that could serve the client better?
  • Are there things Transcelerate can’t accomplish that CROs can?
  • How to facilitate this, given the current paradigm

Attendees interested in meeting with the Synteract team at either of these events may contact Executive Director of Business Development Kim Martinez at 760-529-3440.

See Synteract's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.

About Synteract
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.

# # #

CONTACT:
Amanda Whitlock
Amanda@clearpointagency.com
760-230-2424

x

Contact Synteract

Tell us how to stay in touch with you:

*Required